Market Cap 10.00B
Revenue (ttm) 4.07B
Net Income (ttm) 560.12M
EPS (ttm) N/A
PE Ratio 38.86
Forward PE 8.45
Profit Margin 13.77%
Debt to Equity Ratio 1.35
Volume 461,900
Avg Vol 1,064,212
Day's Range N/A - N/A
Shares Out 60.77M
Stochastic %K 46%
Beta 0.27
Analysts Strong Sell
Price Target $219.00

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 634 7800
Address:
Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland
TokenTreasury
TokenTreasury Feb. 4 at 11:07 AM
$JAZZ relies on acquired products with patent exposures; pipeline sustainability is a persistent question.
0 · Reply
IN0V8
IN0V8 Jan. 29 at 7:43 PM
$JAZZ Buy TD Cowen raises target price to $220 from $205
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 1:52 PM
$JAZZ Share Price: $165.40 Contract Selected: Jun 18, 2026 $165 Calls Buy Zone: $10.67 – $13.18 Target Zone: $17.35 – $21.21 Potential Upside: 54% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TradeTracs
TradeTracs Jan. 27 at 1:53 PM
🚀Today's Top Stocks🚀 $NRIX - Tight price action $JAZZ - Strong relative strength $VRT - Daily chart inverse head and shoulders With the market coming into highs, I am waiting to see if we reject at this level before making any moves. $SPY $QQQ
0 · Reply
TradeTracs
TradeTracs Jan. 26 at 5:12 AM
$JAZZ double inside week still flagging below its post earnings base at 173. 50sma daily support vs Friday lows very nice R:R
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 26 at 4:38 AM
$ZYME $JAZZ excellent overview of the soc and potential impact of zani in gea. https://youtu.be/o53Bx2_eB5I?si=O9vWnGjSod9b6jP4
0 · Reply
Makingmillions192
Makingmillions192 Jan. 23 at 2:31 PM
$LEXX Take a min to go up-vote on Reddit!! https://www.reddit.com/r/pennystocks/s/wM8TyBuhOm $LLY $PFE $JAZZ
1 · Reply
The_Wealth_Maker
The_Wealth_Maker Jan. 23 at 2:28 PM
0 · Reply
Makingmillions192
Makingmillions192 Jan. 23 at 2:23 PM
$LEXX Can’t underestimate the update from yesterday $LLY $NVO $JAZZ Reaching 60 granted patents worldwide moves Lexaria firmly out of early-stage territory and into defensible platform status, which matters far more to pharma than pending IP. The new patents aren’t random: Europe and Australia are costly, high-value jurisdictions, signaling commercial intent. The first EU patent in hypertension is especially meaningful given Europe’s massive cardiovascular market and Lexaria’s recent blood pressure data, reinforcing alignment between clinical results and IP strategy. Expansion of the diabetes patent family in the US shortly after positive GLP-1 Phase 1b data strengthens Lexaria’s leverage exactly where partners are now focused. The emphasis on pursuing commercial relationships only after patents are granted reassures potential partners that legal risk is being actively reduced.
0 · Reply
Evo13
Evo13 Jan. 22 at 3:53 PM
0 · Reply
Latest News on JAZZ
Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Dec 17, 2025, 4:15 PM EST - 6 weeks ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Events


Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 5, 2025, 7:12 AM EST - 2 months ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher


Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 28, 2025, 4:05 PM EDT - 3 months ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.


US FDA approves Jazz Pharma's therapy for lung cancer

Oct 2, 2025, 3:37 PM EDT - 4 months ago

US FDA approves Jazz Pharma's therapy for lung cancer


US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 3:00 PM EDT - 6 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor


Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 10:05 AM EDT - 7 months ago

Is JAZZ Stock Undervalued At $110?


Jazz Pharmaceuticals: One Step Forward, One Back

May 21, 2025, 4:58 AM EDT - 9 months ago

Jazz Pharmaceuticals: One Step Forward, One Back


TokenTreasury
TokenTreasury Feb. 4 at 11:07 AM
$JAZZ relies on acquired products with patent exposures; pipeline sustainability is a persistent question.
0 · Reply
IN0V8
IN0V8 Jan. 29 at 7:43 PM
$JAZZ Buy TD Cowen raises target price to $220 from $205
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 1:52 PM
$JAZZ Share Price: $165.40 Contract Selected: Jun 18, 2026 $165 Calls Buy Zone: $10.67 – $13.18 Target Zone: $17.35 – $21.21 Potential Upside: 54% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TradeTracs
TradeTracs Jan. 27 at 1:53 PM
🚀Today's Top Stocks🚀 $NRIX - Tight price action $JAZZ - Strong relative strength $VRT - Daily chart inverse head and shoulders With the market coming into highs, I am waiting to see if we reject at this level before making any moves. $SPY $QQQ
0 · Reply
TradeTracs
TradeTracs Jan. 26 at 5:12 AM
$JAZZ double inside week still flagging below its post earnings base at 173. 50sma daily support vs Friday lows very nice R:R
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 26 at 4:38 AM
$ZYME $JAZZ excellent overview of the soc and potential impact of zani in gea. https://youtu.be/o53Bx2_eB5I?si=O9vWnGjSod9b6jP4
0 · Reply
Makingmillions192
Makingmillions192 Jan. 23 at 2:31 PM
$LEXX Take a min to go up-vote on Reddit!! https://www.reddit.com/r/pennystocks/s/wM8TyBuhOm $LLY $PFE $JAZZ
1 · Reply
The_Wealth_Maker
The_Wealth_Maker Jan. 23 at 2:28 PM
0 · Reply
Makingmillions192
Makingmillions192 Jan. 23 at 2:23 PM
$LEXX Can’t underestimate the update from yesterday $LLY $NVO $JAZZ Reaching 60 granted patents worldwide moves Lexaria firmly out of early-stage territory and into defensible platform status, which matters far more to pharma than pending IP. The new patents aren’t random: Europe and Australia are costly, high-value jurisdictions, signaling commercial intent. The first EU patent in hypertension is especially meaningful given Europe’s massive cardiovascular market and Lexaria’s recent blood pressure data, reinforcing alignment between clinical results and IP strategy. Expansion of the diabetes patent family in the US shortly after positive GLP-1 Phase 1b data strengthens Lexaria’s leverage exactly where partners are now focused. The emphasis on pursuing commercial relationships only after patents are granted reassures potential partners that legal risk is being actively reduced.
0 · Reply
Evo13
Evo13 Jan. 22 at 3:53 PM
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 21 at 1:46 PM
$IXHL guys a r/s to maintain NASDAQ compliance and get out of the cellar is not the end of the world. Particularly if they time it right (announce it and also expand the share buyback by another $5-10M… or, ideally, a partnership). $JAZZ is getting hosed on their oncology pipeline and Incannex would fit nicely with their epilepsy portfolio… let’s find a deal 🤝
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 3:18 AM
$JAZZ RSI: 48.65, MACD: 0.7615 Vol: 3.88, MA20: 168.38, MA50: 164.58 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeTracs
TradeTracs Jan. 19 at 10:42 PM
$JAZZ still supporting post earnings pop/squat, fade and recovery into 50sma, now nearly double inside day, with inside week for risk parameters
0 · Reply
Estimize
Estimize Jan. 19 at 3:01 PM
Wall St is expecting 6.38 EPS for $JAZZ Q4 [Reporting 03/03 AMC] http://www.estimize.com/intro/jazz?chart=historical&metric_name=eps&utm_co
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 16 at 4:27 PM
Happy to. IQVIA & Symphony & Komodo are the three pharma industry leaders in sales (demand) data. biopharma data in the US is TERRIBLE given the market structure, number of different payers, et al. Often when a product is launched - particularly oral products like $TNXP Tonmya, $INCY Jakafi, $KPTI Xpovio, and even some infusion products like $JAZZ ’s Zepzelca they will block the distributors from selling the data. Usually 10-30% is not captured, but up to 60-95% can be if the pharma company only uses a few distributors & specialty pharamcies. Now this is demand or sales data - for claims data, which shows much more information (with the patient data hidden). However I doubt Tonix is doing that as it can be expensive (you have to pay them to do this - they know how valuable the data is to stock analyst & competitors). I’m hopeful we’ll see the first quarter of demand data from Tonmya soon - which will be its first month (during the holidays!) 😬 Almost to 10K shares long 💎 💪
3 · Reply
JuggernautRaider
JuggernautRaider Jan. 16 at 4:15 PM
$TNXP we should see Symphony Or Komodo sales data for Tonmya soon… assuming Tonix isn’t using contracts with ira distributors to block it like $JAZZ and $KPTI and $INCY do 📊 this is a little trade secret for you all 🤫 get these shares while they’re cheap, I’m buying more ☘️ GLBB 🚀
1 · Reply
Quantumup
Quantumup Jan. 16 at 2:30 PM
Piper Sandler⬆️ $AXSM's PT to $223 from $148, reiterated at an Overweight and said, 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Here's more of what Piper Sandler had to say: https://x.com/Quantumup1/status/2012169826177806564?s=20
0 · Reply
mpap_
mpap_ Jan. 15 at 11:15 PM
$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.
1 · Reply
Chaka1647
Chaka1647 Jan. 14 at 9:05 PM
$FBIOP Bought more today. Risk / Reward is just outstanding. Especially since seeing that $JAZZ sold PRv for such a high number
1 · Reply
JFDI
JFDI Jan. 14 at 7:25 PM
$JAZZ wowza!
0 · Reply
Bigsky007
Bigsky007 Jan. 13 at 8:56 PM
$EVTV $IXHL $JAZZ $LLY $RMD Well BB 23 you picked a good day for a recap. I needed a refresher course.
1 · Reply
BullButter23
BullButter23 Jan. 13 at 8:43 PM
$EVTV Still Bullish but I jumped out a little early to move my profits into $IXHL . They’ve created a first of its kind pill (IHL-42X) to treat Sleep Apnea, which affects over 1 billion people worldwide. It’s been proven to have 83% efficacy with ZERO side effects and has been FDA fast-tracked for Phase 3. IXHL cancelled 350 million warrants and announced the option to exercise a $20M buyback. IHXL has $70M in cash on hand, which is plenty to get this drug through phase 3 and they very recently accelerated vesting its board members. Marijuana was just rescheduled (III) for pharmaceutical purposes, and IXHL owns 19 related patents with 23 more pending, which makes it the largest patented medical marijuana portfolio in the world. Its stock is currently undervalued by 6X and is due for rerate. AGM is scheduled for Thursday. Lots of speculation about a merger or buyout. Potential suitors are $RMD, $LLY, $JAZZ, etc.. with RMD having the most to lose. (CPAP machine maker.) Go check em out
0 · Reply